SCHEMBL17128199

SCHEMBL17128199

CCC(=O)N1[C@@H]2CC[C@H]1CN(c1ccc(Br)cn1)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.43
PDE10A Q9Y233 1/20 0.42
AKR1C3 P42330 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
HDAC1 Q13547 2/20 0.39
JAK2 O60674 7/20 0.39
JAK1 P23458 7/20 0.39
TYK2 P29597 7/20 0.39
CHRM1 P11229 1/20 0.38
PANK3 Q9H999 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
RET P07949 1/20 0.38
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
HTR2A P28223 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18435972 0.86 PDE10A (0.43) PDE10AHDAC1JAK2JAK1TYK2
SCHEMBL18436009 0.86 PDE10A (0.43) PDE10AHDAC1JAK2JAK1TYK2
SCHEMBL17128204 0.85 JAK2 (0.41) ACACBHDAC1JAK2JAK1TYK2
SCHEMBL19012542 0.85 HDAC1 (0.41) AKR1C3HDAC1JAK2JAK1TYK2
SCHEMBL18436982 0.82 ACACB (0.42) ACACBHDAC1JAK2JAK1TYK2
SCHEMBL19012547 0.82 ACACB (0.47) ACACBHDAC1JAK2JAK1TYK2
SCHEMBL19001048 0.82 HPGD (0.42) KDM4EHDAC1JAK2JAK1TYK2
SCHEMBL20034304 0.82 ACACB (0.47) ACACBHDAC1JAK2JAK1TYK2
SCHEMBL19001060 0.82 HPGD (0.42) KDM4EHDAC1JAK2JAK1TYK2
SCHEMBL19001192 0.80 ACACB (0.40) ACACBHDAC1JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124482-B1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) 2019-09-11 EP disclosed
US-9938292-B2 Quinoline derivatives as SMO inhibitors GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-04-10 US disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed
EP-3124482-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-02-01 EP disclosed
WO-2015144001-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS 南京明德新药研发股份有限公司 2015-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS SMO, GLI1, SHH ACACB 3908/4885PDE10A 1457/4885AKR1C3 4072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.